FDA looks for transparency options

After digesting the 1,500 comments from public meetings and then deliberating internally, the FDA has produced 21 draft proposals on public disclosure policies. They are part of an effort launched by Commissioner Margaret Hamburg to give consumers and stakeholders insight into the regulator's decision-making processes.

The proposals, open for public comment for 60 days, are slated for publication in the Federal Register on Friday. The regulator's transparency task force, convened last summer, will review the comments and make recommendations.

The transparency initiative hit a milestone in January with the publication of "FDA Basics," an Internet-based curriculum to help site visitors understand what the regulator does. And one pundit found that in the six months following the launch of the initiative in June, the FDA's transparency increased 77 percent.

- see the release

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.